Schelker, Roland Christian and Herr, Wolfgang and Reichle, Albrecht and Vogelhuber, Martin (2018) Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience. BMC CANCER, 18: 1000. ISSN 1471-2407,
Full text not available from this repository. (Request a copy)Abstract
BackgroundRituximab plus combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is broadly accepted as standard for the treatment of diffuse large B-cell lymphoma (DLBCL). Nevertheless, there is sparsely data concerning the management of elderly patients.MethodsWe performed a retrospective study of treatment with rituximab and low-dose trofosfamide in elderly patients ( 75years) with DLBCL who were not suitable for R-CHOP or R-CHOP-like regimens or who did not consent to aggressive treatment. The choice regarding the qualification for R-CHOP or R-CHOP-like regimen was left to the estimation of the treating physicians.ResultsEleven patients with a median age of 83years (range, 75-90years) were included. The age-adjusted international prognostic index was low risk in one patient, low-intermediate in four patients, high-intermediate in three patients, and high risk in 3 patients. All patients were evaluable for response. Five patients (45%) achieved a complete response, three (27%) a partial response, one (9%) stable disease, and two (18%) progressive disease. The estimated 1-yr overall survival was 54.5%, and the estimated 1-yr progression-free survival 45.5%, however, three patients (27%) were alive without evidence of disease at 16-20months from start of treatment. Main toxicity was leukopenia (36% grade III or IV), whereas grade III/IV non-hematological adverse events did not occur.ConclusionsDue to its potency and low toxicity, trofosfamide/rituximab might represent an alternative therapy for DLBCL of elderly patients not suitable for R-CHOP. This observation, however, should be confirmed in a larger patient population within a prospective clinical trial.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | NON-HODGKINS-LYMPHOMA; DETUDE-DES-LYMPHOMES; PATIENTS AGED 80; PHASE-II TRIAL; CHOP CHEMOTHERAPY; PATIENTS OLDER; PALLIATIVE CHEMOTHERAPY; MAINTENANCE RITUXIMAB; RESPONSE CRITERIA; R-CHOP; Diffuse large B-cell lymphoma; Rituximab; Trofosfamide; Elderly patients |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 05 Dec 2019 07:20 |
| Last Modified: | 05 Dec 2019 07:20 |
| URI: | https://pred.uni-regensburg.de/id/eprint/13680 |
Actions (login required)
 |
View Item |
